Regentis Biomaterials Ltd. (NYSE American: RGNT) is positioning its Gelrin C hydrogel as a practical regenerative medicine solution for cartilage damage, targeting the substantial clinical and economic burden associated with knee osteoarthritis (OA). The company’s cell-free, off-the-shelf hydrogel is administered in a single 10-minute procedure, designed to support cartilage regeneration while avoiding the multiple surgeries, specialized laboratory processing and higher costs typical of cell-based therapies.
With approximately 470,000 knee cartilage repair procedures performed annually in the U.S., representing an estimated $3 billion market, Regentis believes Gelrin C could offer a more scalable approach that fits existing surgical workflows. The product aims to address cartilage defects before they progress to costly OA, which imposes a significant economic toll. Estimates indicate that the annual U.S. economic burden of knee OA ranges from approximately $5.7 billion to $15 billion, with lifetime costs for affected patients potentially exceeding $140,000.
Gelrin C is based on Regentis’ proprietary Gelrin platform technology, which uses synchronized, degradable hydrogel implants to regenerate damaged or diseased tissue, including inflamed cartilage and bone. The hydrogel is eroded and resorbed in the knee, allowing surrounding cells to regenerate cartilage in a controlled and synchronous process. As a cell-free, off-the-shelf treatment, it aims to fill a gap in the market where no such product is currently available.
As Regentis advances Gelrin C toward commercialization, its single-stage design and clinical data could position the company to benefit from growing demand for regenerative treatments that preserve joint health and potentially delay or prevent more expensive degenerative disease. The company’s focus on orthopedic treatments aligns with the increasing need for innovative tissue repair solutions that restore health and enhance quality of life.
For more information, visit the company’s newsroom at https://ibn.fm/RGNT and the full article at https://ibn.fm/yPKU2.
